BCOR::CREBBP Fusion in Malignant Neuroepithelial Tumor of CNS Expands the Spectrum of Methylation Class CNS Tumor with BCOR/BCOR(L1)-fusion

Overview

Journal Acta Neuropathol Commun

Publisher Biomed Central

Specialty Neurology

Date 2024 Apr 18

PMID 38637838

Authors

Azadeh Ebrahimi

Andreas Waha

Jens Schittenhelm

Georg Gohla

Martin U Schuhmann

Torsten Pietsch

Affiliations

Soon will be listed here.

Abstract

Methylation class "CNS tumor with BCOR/BCOR(L1)-fusion" was recently defined based on methylation profiling and tSNE analysis of a series of 21 neuroepithelial tumors with predominant presence of a BCOR fusion and/or characteristic CNV breakpoints at chromosome 22q12.31 and chromosome Xp11.4. Clear diagnostic criteria are still missing for this tumor type, specially that BCOR/BCOR(L1)-fusion is not a consistent finding in these tumors despite being frequent and that none of the Heidelberger classifier versions is able to clearly identify these cases, in particular tumors with alternative fusions other than those involving BCOR, BCORL1, EP300 and CREBBP. In this study, we introduce a BCOR::CREBBP fusion in an adult patient with a right temporomediobasal tumor, for the first time in association with methylation class "CNS tumor with BCOR/BCOR(L1)-fusion" in addition to 35 cases of CNS neuroepithelial tumors with molecular and histopathological characteristics compatible with "CNS tumor with BCOR/BCOR(L1)-fusion" based on a comprehensive literature review and data mining in the repository of 23 published studies on neuroepithelial brain Tumors including 7207 samples of 6761 patients. Based on our index case and the 35 cases found in the literature, we suggest the archetypical histological and molecular features of "CNS tumor with BCOR/BCOR(L1)-fusion". We also present four adult diffuse glioma cases including GBM, IDH-Wildtype and Astrocytoma, IDH-Mutant with CREBBP fusions and describe the necessity of complementary molecular analysis in "CNS tumor with BCOR/BCOR(L1)-alterations for securing a final diagnosis.

Citing Articles

A novel KDM2A::YAP1 fusion in a pediatric supratentorial CNS neoplasm resembling a tumor with BCOR internal tandem duplication.

Tauziede-Espariat A, Metais A, Bochaton D, Servant E, Chotard G, Le Quang M Free Neuropathol. 2025; 6:5.

PMID: 40012953 PMC: 11862909. DOI: 10.17879/freeneuropathology-2025-6152.

Rare Oncogenic Fusions in Pediatric Central Nervous System Tumors: A Case Series and Literature Review.

Ahmed M, Sieben A, Van Genechten T, Libbrecht S, Gilis N, De Praeter M Cancers (Basel). 2024; 16(19).

PMID: 39409964 PMC: 11475864. DOI: 10.3390/cancers16193344.

References

Ellrott K, Bailey M, Saksena G, Covington K, Kandoth C, Stewart C . Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. Cell Syst. 2018; 6(3):271-281.e7. PMC: 6075717. DOI: 10.1016/j.cels.2018.03.002. View

Xu Y, Hou Y, Gao X, Li J, Jiang D, Li Z . Report two adult cases of high-grade neuroepithelial neoplasm harbouring EP300::BCOR fusions with comprehensive molecular detection. Brain Pathol. 2023; 33(6):e13177. PMC: 10580003. DOI: 10.1111/bpa.13177. View

Petralia F, Tignor N, Reva B, Koptyra M, Chowdhury S, Rykunov D . Integrated Proteogenomic Characterization across Major Histological Types of Pediatric Brain Cancer. Cell. 2020; 183(7):1962-1985.e31. PMC: 8143193. DOI: 10.1016/j.cell.2020.10.044. View

Taylor A, Shih J, Ha G, Gao G, Zhang X, Berger A . Genomic and Functional Approaches to Understanding Cancer Aneuploidy. Cancer Cell. 2018; 33(4):676-689.e3. PMC: 6028190. DOI: 10.1016/j.ccell.2018.03.007. View

Ding L, Bailey M, Porta-Pardo E, Thorsson V, Colaprico A, Bertrand D . Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. Cell. 2018; 173(2):305-320.e10. PMC: 5916814. DOI: 10.1016/j.cell.2018.03.033. View

Barthel F, Johnson K, Varn F, Moskalik A, Tanner G, Kocakavuk E . Longitudinal molecular trajectories of diffuse glioma in adults. Nature. 2019; 576(7785):112-120. PMC: 6897368. DOI: 10.1038/s41586-019-1775-1. View

Torre M, Meredith D, Dubuc A, Solomon D, Perry A, Vasudevaraja V . Recurrent EP300-BCOR Fusions in Pediatric Gliomas With Distinct Clinicopathologic Features. J Neuropathol Exp Neurol. 2019; 78(4):305-314. DOI: 10.1093/jnen/nlz011. View

Wu Z, Rajan S, Chung H, Raffeld M, Panneer Selvam P, Schweizer L . Molecular and clinicopathologic characteristics of gliomas with EP300::BCOR fusions. Acta Neuropathol. 2022; 144(6):1175-1178. PMC: 10673683. DOI: 10.1007/s00401-022-02508-2. View

Brennan C, Verhaak R, McKenna A, Campos B, Noushmehr H, Salama S . The somatic genomic landscape of glioblastoma. Cell. 2013; 155(2):462-77. PMC: 3910500. DOI: 10.1016/j.cell.2013.09.034. View

10.

Fukuoka K, Kanemura Y, Shofuda T, Fukushima S, Yamashita S, Narushima D . Significance of molecular classification of ependymomas: C11orf95-RELA fusion-negative supratentorial ependymomas are a heterogeneous group of tumors. Acta Neuropathol Commun. 2018; 6(1):134. PMC: 6278135. DOI: 10.1186/s40478-018-0630-1. View

11.

Liu J, Lichtenberg T, Hoadley K, Poisson L, Lazar A, Cherniack A . An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics. Cell. 2018; 173(2):400-416.e11. PMC: 6066282. DOI: 10.1016/j.cell.2018.02.052. View

12.

Poore G, Kopylova E, Zhu Q, Carpenter C, Fraraccio S, Wandro S . Microbiome analyses of blood and tissues suggest cancer diagnostic approach. Nature. 2020; 579(7800):567-574. PMC: 7500457. DOI: 10.1038/s41586-020-2095-1. View

13.

Ferris S, Velazquez Vega J, Aboian M, Lee J, Van Ziffle J, Onodera C . High-grade neuroepithelial tumor with BCOR exon 15 internal tandem duplication-a comprehensive clinical, radiographic, pathologic, and genomic analysis. Brain Pathol. 2019; 30(1):46-62. PMC: 6859193. DOI: 10.1111/bpa.12747. View

14.

Junco S, Wang R, Gaipa J, Taylor A, Schirf V, Gearhart M . Structure of the polycomb group protein PCGF1 in complex with BCOR reveals basis for binding selectivity of PCGF homologs. Structure. 2013; 21(4):665-71. PMC: 4003909. DOI: 10.1016/j.str.2013.02.013. View

15.

Tauziede-Espariat A, Pierron G, Siegfried A, Guillemot D, Uro-Coste E, Nicaise Y . The EP300:BCOR fusion extends the genetic alteration spectrum defining the new tumoral entity of "CNS tumors with BCOR internal tandem duplication". Acta Neuropathol Commun. 2020; 8(1):178. PMC: 7607816. DOI: 10.1186/s40478-020-01064-8. View

16.

Sanchez-Vega F, Mina M, Armenia J, Chatila W, Luna A, La K . Oncogenic Signaling Pathways in The Cancer Genome Atlas. Cell. 2018; 173(2):321-337.e10. PMC: 6070353. DOI: 10.1016/j.cell.2018.03.035. View

17.

Johnson B, Mazor T, Hong C, Barnes M, Aihara K, McLean C . Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science. 2013; 343(6167):189-193. PMC: 3998672. DOI: 10.1126/science.1239947. View

18.

Yamazaki A, Arai Y, Fukuoka K, Nakano Y, Hama N, Nakata S . Diffusely infiltrating glioma with CREBBP-BCORL1 fusion showing overexpression of not only BCORL1 but BCOR: A case report. Brain Tumor Pathol. 2022; 39(3):171-178. DOI: 10.1007/s10014-022-00435-4. View

19.

Gao Q, Liang W, Foltz S, Mutharasu G, Jayasinghe R, Cao S . Driver Fusions and Their Implications in the Development and Treatment of Human Cancers. Cell Rep. 2018; 23(1):227-238.e3. PMC: 5916809. DOI: 10.1016/j.celrep.2018.03.050. View

20.

Barresi V, Cardoni A, Miele E, Pedace L, Masotto B, Nardini C . CNS tumor with CREBBP::BCORL1 Fusion and pathogenic mutations in BCOR and CREBBP: expanding the spectrum of BCOR-altered tumors. Acta Neuropathol Commun. 2024; 12(1):8. PMC: 10785472. DOI: 10.1186/s40478-024-01726-x. View